Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience, reported insider trading activity on June 20, 2025. The transaction involved a mandatory "sell to cover" of 1,678 shares of Common Stock at $35.755 per share to satisfy tax withholding obligations related to vesting Restricted Stock Units.
Following the transaction, Leproust maintains direct ownership of 645,782 shares of Common Stock. Additionally, she holds several employee stock options:
- 150,879 options at $8.82 (expires 09/28/2027)
- 266,539 options at $26.66 (expires 11/18/2028)
- 131,290 options at $23.33 (expires 10/23/2029)
- 64,950 performance-based options at $67.85 (expires 08/31/2030)
The reported sale was not discretionary but rather mandated by the company's equity incentive plan requirements for tax withholding purposes.
Twist Bioscience Corp (TWST) reported an insider transaction by Dennis Cho, Senior Vice President, Chief Legal Officer & Corporate Secretary. On June 20, 2025, Cho executed a mandatory "sell to cover" transaction involving 230 shares of common stock at a price of $35.755 per share.
The sale was specifically conducted to cover tax withholding obligations related to the vesting of Restricted Stock Units (RSUs) and was not a discretionary trade. Following the transaction, Cho maintains direct beneficial ownership of 104,737 shares of common stock.
This transaction was executed under the company's equity incentive plan requirements, which mandate the satisfaction of tax withholding obligations through "sell to cover" transactions. The Form 4 was filed on June 28, 2025, with the signature of Kendra Fox acting as Attorney-in-Fact for Dennis Cho.